KR860008285A - 심방의 나트륨 이뇨성/혈관 확장성 폴리펩티드의 제조방법 - Google Patents

심방의 나트륨 이뇨성/혈관 확장성 폴리펩티드의 제조방법

Info

Publication number
KR860008285A
KR860008285A KR1019860002983A KR860002983A KR860008285A KR 860008285 A KR860008285 A KR 860008285A KR 1019860002983 A KR1019860002983 A KR 1019860002983A KR 860002983 A KR860002983 A KR 860002983A KR 860008285 A KR860008285 A KR 860008285A
Authority
KR
South Korea
Prior art keywords
polypeptide
preparation
sodium diuretic
vascular dilatation
atrial sodium
Prior art date
Application number
KR1019860002983A
Other languages
English (en)
Other versions
KR950012761B1 (ko
Inventor
케이. 존슨 로린
에이. 아틀라스 스티븐
제이. 맥카티 브리안
에이취. 라라 존
에이. 레윅키 존
Original Assignee
바이오 테크널러지 리서취 파트너스, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/602,117 external-priority patent/US4618600A/en
Application filed by 바이오 테크널러지 리서취 파트너스, 리미티드 filed Critical 바이오 테크널러지 리서취 파트너스, 리미티드
Publication of KR860008285A publication Critical patent/KR860008285A/ko
Application granted granted Critical
Publication of KR950012761B1 publication Critical patent/KR950012761B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C07K14/582—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1019860002983A 1984-04-19 1986-04-16 심방의 나트륨 이뇨성/혈관 확장성 폴리펩티드의 제조방법 KR950012761B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US06/602,117 US4618600A (en) 1984-04-19 1984-04-19 Novel polypeptide diuretic/vasodilators
US61648884A 1984-06-01 1984-06-01
US62263984A 1984-06-20 1984-06-20
USPCT/US85/00658 1985-04-16
PCT/US1985/000658 WO1985004870A1 (en) 1984-04-19 1985-04-16 Novel atrial natriuretic/vasodilator polypeptides

Publications (2)

Publication Number Publication Date
KR860008285A true KR860008285A (ko) 1986-11-14
KR950012761B1 KR950012761B1 (ko) 1995-10-21

Family

ID=27416843

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860002983A KR950012761B1 (ko) 1984-04-19 1986-04-16 심방의 나트륨 이뇨성/혈관 확장성 폴리펩티드의 제조방법

Country Status (8)

Country Link
EP (1) EP0180615B1 (ko)
JP (2) JPH0780907B2 (ko)
KR (1) KR950012761B1 (ko)
AT (1) ATE120759T1 (ko)
DE (1) DE3588006T2 (ko)
IE (1) IE69665B1 (ko)
IL (1) IL74972A (ko)
WO (1) WO1985004870A1 (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198919B1 (en) 1983-04-25 2007-04-03 Genentech, Inc. Use of alpha factor sequences in yeast expression systems
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4851349A (en) * 1984-04-12 1989-07-25 Mitsubishi Chemical Industries Limited Expression vectors encoding cardionatrin and cardiodilatin
AU600652B2 (en) * 1984-06-08 1990-08-23 Hisayuki Matsuo Human atrial natriuretic peptide and gene encoding same
CA1340454C (en) * 1984-06-22 1999-03-23 Yasunori Tawaragi Diuretic peptide and gene coding same
CA1340625C (en) * 1984-06-29 1999-07-06 Peter L. Davies Cloned cardionatrin cdna
JPH0672155B2 (ja) * 1984-08-24 1994-09-14 塩野義製薬株式会社 α−ｈＡＮＰ抗血清作製用ポリペプチド
JPH0672157B2 (ja) * 1984-08-29 1994-09-14 味の素株式会社 新規ペプチド
DE3443257A1 (de) * 1984-11-28 1986-05-28 Bissendorf Peptide GmbH, 3002 Wedemark Mittel enthaltend vollsynthetisches alpha-humanes atriales natriuretisches peptid (alpha-hanap)
DE3509958A1 (de) * 1985-03-20 1986-09-25 Bayer Ag, 5090 Leverkusen Monoklonale antikoerper gegen atriale, natriuretische peptide vom menschen
EP0206769B2 (en) * 1985-06-20 1999-11-10 Fujisawa Pharmaceutical Co., Ltd. A process for the production of alpha-human atrial natriuretic polypeptide
JP3042782B2 (ja) * 1985-11-05 2000-05-22 サイオス インコーポレイテッド 心房性ナトリウム尿***亢進ペプチド類似化合物
EP0223143A3 (en) * 1985-11-05 1989-04-12 California Biotechnology, Inc. Analogs of atrial natriuretic peptides
DE3614833A1 (de) * 1986-01-16 1987-07-23 Hoechst Ag Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
EP0232078A3 (en) * 1986-01-31 1990-03-14 Merck & Co. Inc. Peptides having anf activity
EP0244169A3 (en) * 1986-04-29 1990-04-11 Merck & Co. Inc. Peptides having anf activity
FR2598430B1 (fr) * 1986-05-06 1990-02-02 Roussel Uclaf Nouveaux vecteurs d'expression, leur procede d'obtention et leur application pour exprimer une proteine quelconque dans escherichia coli
EP0246795A3 (en) * 1986-05-20 1990-04-04 Advanced Peptide Development Limited Synthetic natriuretic peptides
CA1339678C (en) * 1986-09-29 1998-02-17 Takeda Chemical Industries Ltd. Atrial natriuretic peptide derivative, its production and use thereof for treating gardiac or cerebral circulatory disease
US5565606A (en) * 1986-10-21 1996-10-15 Hoechst Aktiengesellschaft Synthesis of peptide aminoalkylamides and peptide hydrazides by the solid-phase method
DE3723551A1 (de) * 1987-07-16 1989-01-26 Hoechst Ag Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DK531986D0 (da) * 1986-11-07 1986-11-07 Novo Industri As Peptider
EP0271041A3 (en) * 1986-12-10 1990-04-11 Abbott Laboratories Atrial peptide derivatives
IT1216865B (it) 1987-02-03 1990-03-14 Eniricerche Spa Derivato argininico, procedimento per la sua preparazione e suo impiego nelle sintesi peptidiche.
US5449751A (en) * 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
EP0349545B1 (en) * 1987-03-02 1993-02-03 FORSSMANN, Wolf-Georg, Prof. Dr. med. New cardiodilatin fragment, process for preparing same and use thereof
IL85728A (en) * 1987-03-25 1993-01-14 Bio Mega Inc Fluorine containing atrial natriuretic peptides, their preparation and pharmaceutical compositions containing them
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
EP0309120A3 (en) * 1987-09-23 1990-05-23 Queen's University At Kingston Atrial hypotensive peptide
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) * 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5665704A (en) * 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
ATE226960T1 (de) * 1994-06-02 2002-11-15 Forssmann Wolf Georg Verfahren zur herstellung von cardiodilatin- fragmenten, hochgereinigte cardiodilatin- fragmente und zwischenprodukte zu deren herstellung
US20030203373A1 (en) * 2002-02-20 2003-10-30 Wolf-Dieter Schleuning Method for identifying a pharmacologically active substance
EP2001518B1 (en) 2006-03-30 2013-07-10 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US7795221B2 (en) 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8580746B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
WO2012115772A2 (en) 2011-02-25 2012-08-30 Medtronic, Inc. Therapy for kidney disease and/or heart failure
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0116784B1 (en) * 1982-02-22 1992-06-10 Queen's University At Kingston Atrial natriuretic factor
US4496544A (en) * 1983-11-10 1985-01-29 Washington University Atrial Peptides
US4952561A (en) * 1984-02-07 1990-08-28 Merck & Co., Inc. Cardiac atrial peptides

Also Published As

Publication number Publication date
IL74972A0 (en) 1985-08-30
IE69665B1 (en) 1996-10-02
JPS61501987A (ja) 1986-09-11
AU595158B2 (en) 1990-03-29
WO1985004870A1 (en) 1985-11-07
JPH0780907B2 (ja) 1995-08-30
IL74972A (en) 1991-11-21
KR950012761B1 (ko) 1995-10-21
EP0180615B1 (en) 1995-04-05
IE851006L (en) 1985-10-19
ATE120759T1 (de) 1995-04-15
EP0180615A1 (en) 1986-05-14
DE3588006T2 (de) 1995-08-10
JPH07170988A (ja) 1995-07-11
JPH084512B2 (ja) 1996-01-24
AU4236385A (en) 1985-11-15
EP0180615A4 (en) 1988-06-20
DE3588006D1 (de) 1995-05-11

Similar Documents

Publication Publication Date Title
KR860008285A (ko) 심방의 나트륨 이뇨성/혈관 확장성 폴리펩티드의 제조방법
FI102075B1 (fi) Menetelmä valmistaa glykosyloitu tai glykosyloimaton polypeptidi, rekombinanttinukleiinihappo ja vektorit
DE3473298D1 (en) Method of producing and selectively isolating proteins and polypeptides, recombinant and expression vector therefor and fusion protein able to bind to the constant region of immunoglobulins
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
EP0722461A4 (en) EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE
IL83236A0 (en) Preparation of functional human urokinase proteins
FI104255B1 (fi) Menetelmä ihmisen seerumialbumiinin N-terminaalifragmentteja sisältävien fuusioproteiinien valmistamiseksi
ES547871A0 (es) Metodo para producir la proteina factor recombinante de necrosis de tumores hermanos (tnf) a partir de celulas hospedantes competentes transformadas con un vector de expresion.
DE69317886D1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
GR3007909T3 (ko)
DE3873273D1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.
EP0351244A3 (en) Antibodies and methods for immunochemical assay using them
AU525042B2 (en) Ovulation enhancing peptides
FI934079A (fi) Menetelmä fuusioproteiinin valmistamiseksi

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20051011

Year of fee payment: 11

EXPY Expiration of term